The role of CSTF2 in cancer: from technology to clinical application

References

• Ushijima T, Clark SJ, Tan P. Mapping genomic and epigenomic evolution in cancer ecosystems. Science. 2021 Sep 24;373(6562):1474–1479. doi: 10.1126/science.abh1645
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23;359(6382):1355–1360
   PubMed Web of Science ®Google Scholar
• Yan L, Xu F, Dai CL. Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. J Exp Clin Cancer Res. 2018 Aug 29;37(1):203. doi: 10.1186/s13046-018-0887-z
   PubMedGoogle Scholar
• Sun SN, Hu S, Shang YP, et al. Relevance function of microRNA-708 in the pathogenesis of cancer. Cell Signal. 2019 Nov;63:109390
   PubMed Web of Science ®Google Scholar
• Takagaki Y, MacDonald CC, Shenk T, et al. The human 64-kDa polyadenylylation factor contains a ribonucleoprotein-type RNA binding domain and unusual auxiliary motifs. Proc Natl Acad Sci USA. 1992 Feb 15;89(4):1403–7. doi: 10.1073/pnas.89.4.1403
   PubMed Web of Science ®Google Scholar
• Grozdanov PN, Masoumzadeh E, Kalscheuer VM, et al. A missense mutation in the CSTF2 gene that impairs the function of the RNA recognition motif and causes defects in 3’ end processing is associated with intellectual disability in humans. Nucleic Acids Res. 2020 Sep 25;48(17):9804–9821. doi: 10.1093/nar/gkaa689
   PubMed Web of Science ®Google Scholar
• Youngblood BA, MacDonald CC. CstF-64 is necessary for endoderm differentiation resulting in cardiomyocyte defects. Stem Cell Res. 2014 Nov;13(3 Pt A):413–421. doi: 10.1016/j.scr.2014.09.005
   PubMed Web of Science ®Google Scholar
• Takagaki Y, Seipelt RL, Peterson ML, et al. The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Cell. 1996 Nov 29;87(5):941–52. doi: 10.1016/s0092-8674(00)82000-0
   PubMed Web of Science ®Google Scholar
• Chuvpilo S, Zimmer M, Kerstan A, et al. Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. Immunity. 1999 Feb;10(2):261–9. doi: 10.1016/s1074-7613(00)80026-6
   PubMed Web of Science ®Google Scholar
• Masoumzadeh E, Grozdanov PN, Jetly A, et al. Electrostatic Interactions between CSTF2 and pre-mRNA drive cleavage and polyadenylation. Biophys J. 2022 Feb 15;121(4):607–619. doi: 10.1016/j.bpj.2022.01.005
   PubMed Web of Science ®Google Scholar
• Yan Q, Chen BJ, Hu S, et al. Emerging role of RNF2 in cancer: from bench to bedside. J Cell Physiol. 2021 Aug;236(8):5453–5465. doi: 10.1002/jcp.30260
   PubMed Web of Science ®Google Scholar
• Aragaki M, Takahashi K, Akiyama H, et al. Characterization of a cleavage stimulation factor, 3’ pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clin Cancer Res. 2011 Sep 15;17(18):5889–5900. doi: 10.1158/1078-0432.Ccr-11-0240
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang JX, Luo JH, et al. CSTF2-induced shortening of the RAC1 3‘UTR promotes the pathogenesis of urothelial carcinoma of the bladder. Cancer Res. 2018 Oct 15;78(20):5848–5862. doi: 10.1158/0008-5472.Can-18-0822
   PubMed Web of Science ®Google Scholar
• Zhang MH, Liu J. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3’-kinase/protein kinase B/mammalian target of rapamycin pathway. Bioengineered. 2022 Apr;13(4):10047–10060. doi: 10.1080/21655979.2022.2063100
   PubMed Web of Science ®Google Scholar
• Akman HB, Oyken M, Tuncer T, et al. 3‘UTR shortening and EGF signaling: implications for breast cancer. Hum Mol Genet. 2015 Dec 15;24(24):6910–6920. doi: 10.1093/hmg/ddv391
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen D, Wang Q, et al. Immunological classification of pancreatic carcinomas to identify immune index and provide a strategy for patient stratification. Front Immunol. 2021;12:719105. doi: 10.3389/fimmu.2021.719105
   PubMed Web of Science ®Google Scholar
• Lin A, Ji P, Niu X, et al. CstF64-induced shortening of the BID 3‘UTR promotes esophageal squamous cell carcinoma progression by disrupting ceRNA cross-talk with ZFP36L2. Cancer Res. 2021 Nov 15;81(22):5638–5651. doi: 10.1158/0008-5472.Can-21-1201
   PubMed Web of Science ®Google Scholar
• Gyamfi J, Kim J, Choi J. Cancer as a metabolic disorder. Int J Mol Sci. 2022 Jan 21;23(3):1155
   PubMed Web of Science ®Google Scholar
• Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014 Feb 8;383(9916):549–57
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021 Mar 17;134(7):783–791. doi: 10.1097/cm9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. doi: 10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Dancey JE, Bedard PL, Onetto N, et al. The genetic basis for cancer treatment decisions. Cell. 2012 Feb 3;148(3):409–20. doi: 10.1016/j.cell.2012.01.014
   PubMed Web of Science ®Google Scholar
• Lagergren P, Schandl A, Aaronson NK, et al. Cancer survivorship: an integral part of Europe’s research agenda. Mol Oncol. 2019 Mar;13(3):624–635. doi: 10.1002/1878-0261.12428
   PubMed Web of Science ®Google Scholar
• Tardif S, Akrofi AS, Dass B, et al. Infertility with impaired zona pellucida adhesion of spermatozoa from mice lacking TauCstF-64. Biol Reprod. 2010 Sep;83(3):464–72. doi: 10.1095/biolreprod.109.083238
   PubMed Web of Science ®Google Scholar
• Gruber AJ, Schmidt R, Gruber AR, et al. A comprehensive analysis of 3’ end sequencing data sets reveals novel polyadenylation signals and the repressive role of heterogeneous ribonucleoprotein C on cleavage and polyadenylation. Genome Res. 2016 Aug;26(8):1145–1159. doi: 10.1101/gr.202432.115
   PubMed Web of Science ®Google Scholar
• Salisbury J, Hutchison KW, Graber JH. A multispecies comparison of the metazoan 3’-processing downstream elements and the CstF-64 RNA recognition motif. BMC Genomics. 2006 Mar 16;7(1):55
   PubMedGoogle Scholar
• Deka P, Rajan PK, Perez-Canadillas JM, et al. Protein and RNA dynamics play key roles in determining the specific recognition of GU-rich polyadenylation regulatory elements by human cstf-64 protein. J Mol Biol. 2005 Apr 8;347(4):719–33. doi: 10.1016/j.jmb.2005.01.046
   PubMed Web of Science ®Google Scholar
• Connelly S, Manley JL. A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. Genes Dev. 1988 Apr;2(4):440–52. doi: 10.1101/gad.2.4.440
   PubMed Web of Science ®Google Scholar
• Zhang W, Wan Y, Zhang Y, et al. CSTF2 acts as a prognostic marker correlated with immune infiltration in hepatocellular carcinoma. Cancer Manag Res. 2022;14:2691–2709. doi: 10.2147/cmar.S359545
   PubMed Web of Science ®Google Scholar
• Wei Y, Luo H, Yee PP, et al. Paraspeckle protein NONO promotes TAZ phase separation in the nucleus to drive the oncogenic transcriptional program. Adv Sci. 2021 Dec;8(24):e2102653. doi: 10.1002/advs.202102653
   Web of Science ®Google Scholar
• Okada M, Cheeseman IM, Hori T, et al. The CENP-H-I complex is required for the efficient incorporation of newly synthesized CENP-A into centromeres. Nat Cell Biol. 2006 May;8(5):446–457. doi: 10.1038/ncb1396
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Chu HJ, et al. Centromere protein I (CENP-I) is upregulated in gastric cancer, predicts poor prognosis, and promotes tumor cell proliferation and migration. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211045510. doi: 10.1177/15330338211045510
   Web of Science ®Google Scholar
• Thangavelu PU, Lin CY, Vaidyanathan S, et al. Overexpression of the E2F target gene CENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer. Oncotarget. 2017 Sep 22;8(37):62167–62182. doi: 10.18632/oncotarget.19131
   PubMedGoogle Scholar
• Yu Q, Yin L, Jian Y, et al. Downregulation of PHF6 inhibits cell proliferation and migration in hepatocellular carcinoma. Cancer Biother Radiopharm. 2019 May;34(4):245–251. doi: 10.1089/cbr.2018.2671
   PubMed Web of Science ®Google Scholar
• Yu Q, Zhou J, Jian Y, et al. MicroRNA-214 suppresses cell proliferation and migration and cell metabolism by targeting PDK2 and PHF6 in hepatocellular carcinoma. Cell Biol Int. 2020 Jan;44(1):117–126. doi: 10.1002/cbin.11207
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang X, Lei W, et al. Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer. J Transl Med. 2019 Aug 7;17(1):257. doi: 10.1186/s12967-019-1986-0
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li X, Deng S, et al. CSTF2 mediated mRNA N(6)-methyladenosine modification drives pancreatic ductal adenocarcinoma m(6)A subtypes. Nat Commun. 2023 Oct 10;14(1):6334. doi: 10.1038/s41467-023-41861-y
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409–436. doi: 10.3322/caac.21731
   PubMed Web of Science ®Google Scholar
• Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020 Mar;41(1):1–24. doi: 10.1016/j.ccm.2019.10.001
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Daigo Y, Ishikawa N, et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol. 2006 Apr;28(4):799–805.
   PubMed Web of Science ®Google Scholar
• Kakiuchi S, Daigo Y, Tsunoda T, et al. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res. 2003 May;1(7):485–99.
   PubMed Web of Science ®Google Scholar
• Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029–43. doi: 10.1093/hmg/ddh331
   PubMed Web of Science ®Google Scholar
• Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 2006 Sep;29(3):567–75.
   PubMed Web of Science ®Google Scholar
• Yeh HS, Yong J. Alternative Polyadenylation of mRNAs: 3’-Untranslated Region Matters in Gene Expression. Mol Cells. 2016 Apr 30;39(4):281–285. doi: 10.14348/molcells.2016.0035
   PubMed Web of Science ®Google Scholar
• Galsky MD, Pal SK, Lin SW, et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States. Bladder Cancer. 2018 Apr 26;4(2):227–238. doi: 10.3233/blc-170149
   PubMed Web of Science ®Google Scholar
• Marei H, Malliri A. Rac1 in human diseases: the therapeutic potential of targeting Rac1 signaling regulatory mechanisms. Small GTPases. 2017 Jul 3;8(3):139–163. doi: 10.1080/21541248.2016.1211398
   PubMedGoogle Scholar
• Volanis D, Zaravinos A, Kadiyska T, et al. Expression profile of Rho kinases in urinary bladder cancer. J Buon. 2011 Jul-Sep;16(3):511–21.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang H, Shi L, et al. Inhibition of Rac1 activity induces G1/S phase arrest through the GSK3/cyclin D1 pathway in human cancer cells. Oncol Rep. 2014 Oct;32(4):1395–400. doi: 10.3892/or.2014.3388
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu N, Gao N, et al. Small G Rac1 is involved in replication cycle of dengue serotype 2 virus in EAhy926 cells via the regulation of actin cytoskeleton. Sci China Life Sci. 2016 May;59(5):487–94. doi: 10.1007/s11427-016-5042-5
   PubMed Web of Science ®Google Scholar
• Gilles H, Garbutt T, Landrum J. Hepatocellular Carcinoma. Crit Care Nurs Clin North Am. 2022 Sep;34(3):289–301. doi: 10.1016/j.cnc.2022.04.004
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236. doi: 10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016 Jun;25(2):74–85. doi: 10.1016/j.suronc.2016.03.002
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589–604. doi: 10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and caucasian patients: a single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer. 2007 Aug 15;110(4):876–884. doi: 10.1002/cncr.22836
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429–4434. doi: 10.1158/1078-0432.Ccr-06-3045
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov 15;113(10):2638–45. doi: 10.1002/cncr.23930
   PubMed Web of Science ®Google Scholar
• Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015 Jun;12(2):106–16. doi: 10.7497/j.issn.2095-3941.2015.0030
   PubMed Web of Science ®Google Scholar
• Shell SA, Hesse C, Morris SM Jr., et al. Elevated levels of the 64-kDa cleavage stimulatory factor (CstF-64) in lipopolysaccharide-stimulated macrophages influence gene expression and induce alternative poly(A) site selection. J Biol Chem. 2005 Dec 2;280(48):39950–61. doi: 10.1074/jbc.M508848200
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Wood LD, Canto MI, Jaffee EM, et al. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022 Aug;163(2):386–402.e1. doi: 10.1053/j.gastro.2022.03.056
   PubMed Web of Science ®Google Scholar
• Lin DC, Dinh HQ, Xie JJ, et al. Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas. Gut. 2018 Oct;67(10):1769–1779. doi: 10.1136/gutjnl-2017-314607
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333–348. doi: 10.1038/s41575-018-0005-x
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018 Mar 23;359(6382):1350–1355. doi: 10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Fakhry C, Zevallos JP, Eisele DW. Imbalance between clinical and pathologic staging in the updated American joint commission on cancer staging system for human papillomavirus-positive oropharyngeal cancer. J Clin Oncol. 2018 Jan 20;36(3):217–219. doi: 10.1200/jco.2017.75.2063
   PubMed Web of Science ®Google Scholar
• Icard P, Fournel L, Wu Z, et al. Interconnection between metabolism and cell cycle in cancer. Trends Biochem Sci. 2019 Jun;44(6):490–501. doi: 10.1016/j.tibs.2018.12.007
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019 Dec;59:125–132. doi: 10.1016/j.semcancer.2019.07.009
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020 Dec 4;13(1):165. doi: 10.1186/s13045-020-00990-3
   PubMed Web of Science ®Google Scholar
• Wang R, Sun Q, Wang P, et al. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget. 2016 Feb 2;7(5):5754–68. doi: 10.18632/oncotarget.6805
   PubMedGoogle Scholar
• Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020 Jul 6;39(1):126. doi: 10.1186/s13046-020-01629-4
   PubMed Web of Science ®Google Scholar
• Lachenmayer A, Alsinet C, Chang CY, et al. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis. 2010 Jul;42(Suppl 3):S264–72. (0 3). doi: 10.1016/s1590-8658(10)60515-4
   PubMedGoogle Scholar
• Bortolotto LF, Barbosa FR, Silva G, et al. Cytotoxicity of trans-chalcone and licochalcone a against breast cancer cells is due to apoptosis induction and cell cycle arrest. Biomed Pharmacother. 2017 Jan;85:425–433
   PubMed Web of Science ®Google Scholar
• He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5
   PubMed Web of Science ®Google Scholar
• Xue S, Zhou Y, Zhang J, et al. Anemoside B4 exerts anti-cancer effect by inducing apoptosis and autophagy through inhibiton of PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Am J Transl Res. 2019;11(4):2580–2589.
   PubMed Web of Science ®Google Scholar
• Condorelli DF, Privitera AP, Barresi V. Chromosomal density of cancer up-regulated genes, aberrant enhancer activity and cancer fitness genes are associated with transcriptional cis-effects of broad copy number gains in colorectal cancer. Int J Mol Sci. 2019 Sep 19;20(18):4652
   PubMed Web of Science ®Google Scholar
• Xia Z, Donehower LA, Cooper TA, et al. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. Nat Commun. 2014 Nov 20;5(1):5274. doi: 10.1038/ncomms6274
   PubMedGoogle Scholar
• Mao Z, Zhao H, Qin Y, et al. Post-transcriptional dysregulation of microRNA and alternative polyadenylation in colorectal cancer. Front Genet. 2020;11:64. doi: 10.3389/fgene.2020.00064
   PubMed Web of Science ®Google Scholar
• Wang M, Huang S, Chen Z, et al. Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer. 2020 Nov 23;20(1):1136. doi: 10.1186/s12885-020-07625-3
   PubMed Web of Science ®Google Scholar
• Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003 Jan 1;63(1):1–5.
   PubMed Web of Science ®Google Scholar
• Daveri E, Adamo AM, Alfine E, et al. Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway. Redox Biol. 2021 Jan;38:101830
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan;16(1):15–31. doi: 10.1517/14728222.2011.648617
   PubMed Web of Science ®Google Scholar
• Feng Y, Dai X, Li X, et al. EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif. 2012 Oct;45(5):413–419. doi: 10.1111/j.1365-2184.2012.00837.x
   PubMed Web of Science ®Google Scholar
• Mayr C, Bartel DP. Widespread shortening of 3‘UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009 Aug 21;138(4):673–684. doi: 10.1016/j.cell.2009.06.016
   PubMed Web of Science ®Google Scholar
• Chen Z, Hao W, Tang J, et al. CSTF2 Promotes Hepatocarcinogenesis and Hepatocellular Carcinoma Progression via Aerobic Glycolysis. Front Oncol. 2022;12:897804. doi: 10.3389/fonc.2022.897804
   PubMed Web of Science ®Google Scholar
• Takahashi K, Furukawa C, Takano A, et al. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 2006 Oct 1;66(19):9408–19. doi: 10.1158/0008-5472.Can-06-1349
   PubMed Web of Science ®Google Scholar
• Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013 Feb 15;339(6121):819–23. doi: 10.1126/science.1231143
   PubMed Web of Science ®Google Scholar
• Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014 Oct 9;159(2):440–55. doi: 10.1016/j.cell.2014.09.014
   PubMed Web of Science ®Google Scholar
• Sonoiki E, Ng CL, Lee MC, et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nat Commun. 2017 Mar 6;8(1):14574. doi: 10.1038/ncomms14574
   PubMedGoogle Scholar
• Vivori C, Papasaikas P, Stadhouders R, et al. Dynamics of alternative splicing during somatic cell reprogramming reveals functions for RNA-binding proteins CPSF3, hnRNP UL1, and TIA1. Genome Biol. 2021 Jun 3;22(1):171. doi: 10.1186/s13059-021-02372-5
   PubMed Web of Science ®Google Scholar
• Sun Y, Hamilton K, Tong L. Recent molecular insights into canonical pre-mRNA 3’-end processing. Transcription. 2020 Apr;11(2):83–96. doi: 10.1080/21541264.2020.1777047
   PubMed Web of Science ®Google Scholar
• Konermann S, Brigham MD, Trevino AE, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015 Jan 29;517(7536):583–8. doi: 10.1038/nature14136
   PubMed Web of Science ®Google Scholar
• Zalatan JG, Lee ME, Almeida R, et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell. 2015 Jan 15;160(1–2):339–50. doi: 10.1016/j.cell.2014.11.052
   PubMed Web of Science ®Google Scholar
• Zeidler R, de Freitas Soares BL, Bader A, et al. Molecular epigenetic targets for liver diseases: current challenges and future prospects. Drug Discov Today. 2017 Nov;22(11):1620–1636. doi: 10.1016/j.drudis.2017.07.008
   PubMed Web of Science ®Google Scholar
• Li JY, Chen YP, Li YQ, et al. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer. 2021 Feb 4;20(1):27. doi: 10.1186/s12943-021-01317-7
   PubMed Web of Science ®Google Scholar
• Nagaratnam N, Karunanayake EH, Tennekoon KH, et al. In silico characterization of a RNA binding protein of cattle filarial parasite Setaria digitata. Bioinformation. 2014;10(8):512–7. doi: 10.6026/97320630010512
   PubMedGoogle Scholar
• Guo S, Deng CX. Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 2018;14(14):2083–2093. doi: 10.7150/ijbs.25720
   PubMed Web of Science ®Google Scholar
• Kudinov AE, Karanicolas J, Golemis EA, et al. Musashi RNA-Binding proteins as cancer drivers and novel therapeutic targets. Clin Cancer Res. 2017 May 1;23(9):2143–2153. doi: 10.1158/1078-0432.Ccr-16-2728
   PubMed Web of Science ®Google Scholar
• Qin H, Ni H, Liu Y, et al. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020 Jul 11;13(1):90. doi: 10.1186/s13045-020-00927-w
   PubMed Web of Science ®Google Scholar